May 1, 2024 04:53 AM EDTUpdated 06:31 AM
Pharma
FDA+

Neu­ro­crine wins ap­proval of In­grez­za 'sprin­kle' for­mu­la­tion for pa­tients with trou­ble swal­low­ing

Nicole DeFeudis

Editor

Neu­ro­crine Bio­sciences won FDA ap­proval on Tues­day for a new for­mu­la­tion that may help In­grez­za go down in a more de­light­ful …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times